Volume 31, Issue 2 pp. 92-94
Full Access

Bacitracin: a significant sensitizer in leg ulcer patients?

I. Zaki

Corresponding Author

I. Zaki

Department of Dermatology, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, UK

Irshad Zaki, Department of Dermatology, University Hospital, Queens Medical Centre, Derby Road, Nottingham, NC7 2UH, UKSearch for more papers by this author
L. Shall

L. Shall

Department of Dermatology, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, UK

Search for more papers by this author
K. L. Dalziel

K. L. Dalziel

Department of Dermatology, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, UK

Search for more papers by this author
First published: August 1994
Citations: 50

Abstract

We report the results of patch testing 85 patients with either long-standing venous ulceration or eczema complicating their leg ulcers. As previously reported, lanolin and its derivatives and topical antibiotics were the most frequent sensitizers. However, unlike previously published data, we found bacitracin to be the most potent sensitizer of all topical antiboitics tested. There were no positive reactions in a control group of patients, although we were unable to repeat the patch tests in patients with a positive reaction to bacitracin. In the past 10 years, our department has used a proprietary mixture of potymyxin and bacitracin in treating infected leg ulcers and other dermatoses. It is therefore possible that chronic usage of topical bacitracin on leg ulcers carries a significant risk of contact sensitization.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.